HP Donates D300e BioPrinters to NGOs, Universities, and Research Institutions to Accelerate Drug and Vaccine Research to Combat COVID-19

Donates $100,000 (US) to Spanish National Research Council (CSIC) through the HP Foundation to research possible treatments for the virus

News highlights:

• Deploys BioPrinters to four major research facilities:

_° Spanish National Research Council (CSIC) (Spain), the largest and leading public research institution in Spain.
_° Center for Nuclear Receptors and Cell Signaling (CNRCS) at University of Houston (U.S.), which conducts a wide range of cutting-edge research to develop therapeutics for various diseases including viral diseases, cancer, neurodegenerative diseases and metabolic diseases.
_° Monoclonal Antibody Discovery Laboratory at Fondazione Toscana Life Sciences (Italy), which focuses on monoclonal antibody (mAb) discovery against infectious diseases.
_° Grenoble Alpes University Hospital (CHUGA) (France), one of the largest research and teaching hospitals in France, which focuses on diagnosis and follow-up of acute or chronic human viral infections.

PALO ALTO, Calif., July 13, 2020 (GLOBE NEWSWIRE) -- HP Inc. (NYSE: HPQ) today announced the deployment of HP D300e BioPrinters, associated supply cassettes, and training, free of charge, to research laboratories in the U.S. and Europe to help accelerate drug and vaccine research to combat COVID-19.

“Each of us has a role to play to combat this pandemic, and HP and the HP Foundation have donated millions of dollars in products and grants to support local communities impacted by COVID-19 worldwide,” said Annette Friskopp, Global Head and General Manager, Specialty Printing Systems, HP Inc. “We are inspired by the research being conducted by laboratories worldwide to better understand this pandemic, and if the HP D300e BioPrinter in the hands of these scientists can help accelerate their drug and vaccine research, it’s our responsibility to step forward and dedicate resources and technology to make it happen.”

How it works
The BioPrinter with inkjet printing technology enables automated laboratory dispensing to “print” pharmaceutical samples instead of ink. The BioPrinter accurately dispenses or “prints” volumes from picoliters to microliters for fast, reliable dispensing of small molecules and biomolecules. The BioPrinter enables labs to eliminate serial dilution from dose response workflows, miniaturize qPCR reaction volumes, and easily dispense any volume in any well for a broad array of low-volume dispensing applications in drug discovery, genomics, and proteomics research.